Clinical trials: Respiratory Physiological Phenomena
Mild Persistent Asthma
Dose Response AMP Challenge Study With Beclometasone Dipropionate (BDP)/Formoterol Pressurised Metered Dose Inhaler (pMDI)
The aim of this exploratory investigation is to evaluate if the Forced Expiratory Volume in the 1st second (FEV1) measurements, fractional exhaled nitric oxide (FENO) and Provocative Concentration 20 (PC20) after Adenosine…
- Trial name
- NCT01343745
- Testing
- BDP/formoterol
- Where
- United Kingdom
- Volunteers
- 18 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
Stroke, Muscle Spasticity
Safety Study of Botulinum Toxin Type A in Post-Upper Limb Stroke Patients With Reduced Lung Function
The purpose of this study is to evaluate the safety of injections of botulinum toxin Type A in patients with reduced lung function and focal upper limb poststroke spasticity
- Conditions
- Stroke, Muscle Spasticity, Motor Neuron Disease
- Trial name
- NCT00076687
- Testing
- botulinum toxin Type A, saline
- Where
- 4 sites in United States, Czechia and 2 more
- Volunteers
- 155 people
- Sponsor
- Allergan
Cough
Accuracy of Cough Detection in Healthy Adults
Cough is part of the defense mechanism to protect the lung from foreign particles and remove secretions from the airways. However, at times it becomes a bothersome, annoying symptom that interferes with the quality of life, sleep…
- Trial name
- NCT00907491
- Testing
- pulmonary sounds analyzer
- Where
- Israel
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- KarmelSonix Ltd.
Idiopathic Pulmonary Fibrosis
A Study to Find Out Whether BI 765423 Has an Effect on Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF) With or Without Standard Treatment
This study is open to adults who are at least 40 years old and have idiopathic pulmonary fibrosis (IPF). People can participate in the study if they have a forced vital capacity (FVC) greater than or equal to 45% of the predicted…
- Trial name
- NCT07036523
- Testing
- BI 765423
- Where
- 46 sites in United States, Australia and 8 more
- Volunteers
- 81 people
- Sponsor
- Boehringer Ingelheim
Chronic Obstructive Pulmonary Disease
NVA237 BID Versus Placebo Twelve-week Efficacy Study
The study serves to determine whether the treatment of patients with stable, symptomatic Chronic Obstructive Pulmonary Disease (COPD) with the investigational drug NVA237 is efficient and safe.
- Trial name
- NCT01715298
- Testing
- NVA237
- Where
- 59 sites in United States
- Volunteers
- 432 people
- Sponsor
- Novartis Pharmaceuticals
COPD
24-hour Lung Function in Subjects With Moderate to Very Severe COPD After Treatment With PT003 and Placebo MDI
Randomized, Phase IIIb, Two-period, Two-treatment Double-blind, Multi-center, Crossover Study to Evaluate the 24-hour Lung Function Profile in Subjects with Moderate to Very Severe COPD after 4 Weeks of Treatment with PT003 and…
- Trial name
- NCT02347085
- Testing
- GFF MDI (PT003)
- Volunteers
- 43 people
- Sponsor
- Pearl Therapeutics, Inc.
COPD, Heterogeneous Emphysema
To Improve Lung Function and Symptoms for Emphysema Patients Using Zephyr Valves
To compare the clinical outcomes of Endoscopic Lung Volume Reduction (ELVR) using Pulmonx Zephyr Valves vs. Standard of Care (SoC) in the treatment of heterogeneous emphysema subjects in a controlled trial design setting.
- Trial name
- TRANSFORM (NCT02022683)
- Testing
- ELVR (Endoscopic Lung Volume Reduction) with Zephyr Valves
- Where
- 17 sites in Belgium, France and 4 more
- Volunteers
- 97 people
- Sponsor
- Pulmonx Corporation
Chronic Obstructive Pulmonary Disease (COPD)
WearME-Pro Phase II: Remote Use Usability and Longitudinal Validation Study (Patch Form Factor).
This Phase II investigation evaluates the safety, usability, and clinical performance of the WearME-Pro patch system for remote monitoring of adults with COPD in a home-use environment.
- Trial name
- WearME-Pro (NCT07430605)
- Testing
- WearME-Pro Patch System, FDA-cleared handheld spirometer (reference comparator), Cardea SOLO ECG patch (optional subset; exploratory HR reference)
- Where
- 3 sites in United States
- Volunteers
- 82 people
- Sponsor
- LASARRUS Clinic and Research Center
Idiopathic Pulmonary Fibrosis
NAL ER IPF Respiratory Function and Safety Study
The primary purpose of this study is to assess the safety and tolerability of escalating doses of NAL ER and to evaluate its effect on respiratory function in participants with IPF.
- Trial name
- NCT07036029
- Testing
- NAL ER
- Where
- 2 sites in United States, United Kingdom
- Volunteers
- 9 people
- Sponsor
- Trevi Therapeutics
Pulmonary Disease, Chronic Obstructive
The ENERGITO® 2 Study Compares 2 Inhaled Medicines for Chronic Obstructive Pulmonary Disease (COPD). One Medicine is a Combination of Tiotropium and Olodaterol (Stiolto®) Taken Using the Respimat® Inhaler and the Other Medicine is a Combination of Fluticasone and Salmeterol Taken Using the Diskus
The primary objective of the trial is to show superiority in lung function of once daily (2 inhalations) treatment with orally inhaled tiotropium+olodaterol fixed dose combination to twice daily (one inhalation) treatment with…
- Trial name
- NCT03240575
- Testing
- Tiotropium, Olodaterol, Fluticasone propionate
- Where
- 45 sites in United States
- Volunteers
- 302 people
- Sponsor
- Boehringer Ingelheim